A Phase 2/3 interventional study of deucrictibant and deucrictibant in Hereditary Angioedema, Hereditary Angioedema Type I and Hereditary Angioedema Type II, sponsored by Pharvaris Netherlands B.V.. Enrolling by invitation at 60 sites in 24 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Pharvaris Netherlands B.V. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.
Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 8th largest by planned enrollment of the 74 interventional ones that give a count, is one of 8 that started in 2022, is one of 4 in phase 2/3, reaches primary completion later than 5 of the 17 other live ones, and was the 55th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:
KalVista Pharmaceuticals, Ltd. · Sites in United States
Ages 12+
Ionis Pharmaceuticals, Inc. · Sites in United States, Australia, Italy and 2 more countries
Ages 2–11
ADARx Pharmaceuticals, Inc. · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Pharvaris Netherlands B.V. · Sites in United States, Australia, Austria and 13 more countries
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 42 · Phase 4 6
First in 2004; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 57 across the 74 interventional studies, 168 across the 7 observational. Of the 62 that completed or were terminated, 47 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 84 have an industry lead sponsor. The 10 most frequent:
Pharvaris Netherlands B.V. is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Pharvaris Netherlands B.V. has 8 studies filed under Angioedemas, Hereditary — fewer than ten, so there is no comparison to draw.
7 of the studies in Angioedemas, Hereditary with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06842823Phase 3Astria Therapeutics, Inc.A Study of Navenibart in Participants With Hereditary Angioedema | 2026-12 |
| NCT05392114Phase 3Ionis Pharmaceuticals, Inc.A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | 2026-12 |
| NCT05396105Phase 3Pharvaris Netherlands B.V.Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | 2027-06 |
| NCT07266805Phase 3Pharvaris Netherlands B.V.Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency | 2027-06 |
| NCT06960213Phase 3ADARx Pharmaceuticals, Inc.STOP-HAE: A Phase 3 Study of ADX-324 in HAE | 2027-11-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 84 studies in Angioedemas, Hereditary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks. The study will enroll participants from Study PHA022121-C201 (NCT04618211), Study PHA022121-C306 (NCT06343779) and deucrictibant treatment naïve HAE-nC1INH adult participants who elect to participate in this extension study and meet the eligibility requirements.
Part A of the study will enroll adult participants from Study PHA022121-C201. The double-blind treatment assignment from Study PHA022121-C201 will be maintained.
Part B is open-label treatment and includes participants rolling over from Part A, participants from Study PHA022121-C201 who did not participate in Part A, participants aged 12 years and older with HAE type I, type II, or HAE-nC1INH rolling over from Study PHA022121-C306, and deucrictibant treatment naïve adult participants with HAE-nC1INH who elect to participate in this extension study and meet the eligibility requirements.
Key Inclusion Criteria:
Adult participants with HAE type III (HAE-nC1INH) who are deucrictibant-treatment naïve, must meet all of the following:
i. Recurrent angioedema attacks with diagnostic testing results obtained during screening to confirm C1INH function ≥50% of normal and C4 level not below the lower level of the normal range performed by the central laboratory.
ii. Must either have:
Documented genetic mutation associated with HAE-nC1INH as listed in the Hereditary Angioedema Association (HAEA) and World Allergy Organization (WAO)/European Academy of Allergy and Clinical Immunology (EAACI) Guidelines.
OR
iii. Attacks not responding to treatments with high-dose antihistamine (cetirizine 40 mg/day or equivalent high-dose second-generation antihistamine medication) and no clinical attack symptoms relief if treated with , montelukast, or omalizumab.
iv. Documented effective attack symptom relief with on-demand icatibant treatment.
v. A history of at least 1 HAE attack in the last 3 months prior to Screening
Key Exclusion Criteria:
Participants who have recently used short or long-term HAE prophylaxis or on-demand HAE treatment will not be excluded from the study provided the following is observed (i.e., study screening or enrollment/rollover should be delayed allowing for washout):
i. For Part A:
ii. For Part B:
a. If a participant is receiving long-term prophylactic therapy with a medication indicated for HAE:, eg, plasma-derived C1INH, danazol at less than or equal to 200 mg/day, antifibrinolytics, berotralstat, or lanadelumab, they must be on a stable dose and regimen for at least 3 months before screening and intends to remain on the same dose for the duration of the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive the dose of deucrictibant they were randomized to in the PHA022121-C201 study (low, medium, or high dose, each consisting of 3 capsules of deucrictibant or matching placebo) for oral use for on-demand treatment of HAE attacks.
Drug: deucrictibant
Participants will receive deucrictibant soft capsules for oral use for on-demand treatment of HAE attacks.
Drug: deucrictibant
3 capsules of deucrictibant or matching placebo will be administered orally for each HAE attack
Also known as: PHVS416, PHA121, PHA-022121
deucrictibant soft capsules will be administered orally for each HAE attack
Also known as: PHVS416, PHA121, PHA-022121
Treatment-emergent Adverse Events (TEAEs), treatment-related TEAEs, treatment-emergent serious adverse events (TESAEs), treatment-related TESAEs, and TEAEs leading to deucrictibant discontinuation
Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
Heart Rate
Descriptive in nature, no formal statistical hypothesis testing will be performed.
Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
Blood pressure
Systolic and diastolic blood pressure will be measured. Descriptive in nature, no formal statistical hypothesis testing will be performed.
Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
Body temperature
Descriptive in nature, no formal statistical hypothesis testing will be performed.
Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
Clinical laboratory tests
hematology, blood chemistry, urinalysis
Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
Electrocardiograms
Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
Physical Examination
Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
Time to onset of symptom relief, defined as Patient Global Impression of Change (PGI-C) rating of at least "a little better" for 2 consecutive timepoints within 12 hours post-treatment
PGI-C evaluates the change in the attack symptoms over time with a 7-point response scale.
Time frame: Assessed from 1 hour to 12 hours post-treatment
Time to substantial symptom relief, defined as achieving PGI-C rating of at least "better" for 2 consecutive timepoints within 12 hours post-treatment
PGI-C evaluates the change in the attack symptoms over time with a 7-point response scale.
Time frame: Assessed from 1 hour to 12 hours post-treatment
Time to substantial symptom relief by Patient Global Impression of Severity (PGI-S), defined as achieving ≥1 point reduction in PGI-S from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment
PGI-S evaluates the severity of attack symptoms with a 5-point response scale.
Time frame: Assessed from pre-treatment to 12 hours post-treatment
Proportion of attacks achieving symptom resolution, defined as achieving PGI-S rating of "none" at 24 hours post-treatment.
Time frame: At 24 hours post-treatment
Proportion of deucrictibant-treated attacks requiring rescue medication within 24 hours post-treatment
Time frame: Assessed from pre-treatment to 24 hours post-treatment
Time to onset of symptom relief, assessed by a ≥30% reduction in VAS-3/ VAS-5 (Part A) or AMRA (Part B) composite score from the pre-treatment score
VAS/AMRA scores range between 0 and 100. A larger reduction means a better outcome.
Time frame: Assessed from pre-treatment to 48 hours post-treatment
Time to substantial symptom relief by VAS-3/ VAS-5 (Part A) or AMRA (Part B), defined as a ≥50% reduction in VAS-3/ VAS-5 (Part A) or AMRA (Part B) composite score from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment
VAS/AMRA scores range between 0 and 100. A larger reduction means a better outcome.
Time frame: Assessed from pre-treatment to 12 hours post-treatment
Proportion of study drug-treated attacks reaching almost complete or complete symptom relief by VAS-3/ VAS-5 (Part A) or AMRA (Part B), defined as all item scores in VAS-3/ VAS-5/ AMRA having a value ≤10 at 24 hours post-treatment
Almost complete or complete symptom relief is defined as all individual item scores in VAS/AMRA having a value ≤10 sustained for 2 consecutive timepoints.
Time frame: At 24 hours post-treatment
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Jun 2027, 54 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucrictibant
Pharvaris Netherlands B.V.